A better understanding of factors influencing retention in breast cancer risk education and prevention programs can improve the design and effectiveness of such programs. Such information may also be useful to researchers seeking to maximize full retention in research trials involving low risk and low perceived benefit by the participants. These data are from a population-based study of 481 women from the Seattle, Washington, area, with diverse levels of breast cancer risk. This study sought to describe motivations for retention, to relate motivation variables to demographic characteristics, and to evaluate predictors of retention. Increasing age predicted study assessment completion, and both cancer worry and White ethnicity predicted intervention retention.
American Association for Public Opinion Research. (1999). Standard definitions: Final dispositions of case codes and outcome rates for RDD Telephone surveys and in-person household surveys. Ann Arbor, MI: Author.
2.
Bevan, E. G., Chee, L. C., McGhee, S. M., & McInnes, G. T. (1993). Patients' attitudes to participation in clinical trials. British Journal of Clinical Pharmacology,35, 204-207.
3.
Bowen, D., McTiernan, A., Burke, W., Powers, D.Pruski, J., Durfy, S., et al. (1999). Participation in breast cancer risk counseling among women with a family history. Cancer Epidemiology, Biomarkers & Prevention,8, 581-585.
4.
Bowen, D. J., Cartmel, B., Barnett, M., Goodman, G., & Omenn, G. S. (1999). Predictors of participant retention in two chemoprevention feasibility trials. Annals of Behavioral Medicine,21, 210-215.
5.
Bowen, D. J., Thornquist, M., Anderson, K., Barnett, M., Powell, C., Goodman, G., et al. (2003). Stopping the active intervention: CARET. Controlled Clinical Trials,24, 39-50.
6.
Burke, W., Culver, J. O., Bowen, D., Lowry, D., Durfy, S., McTiernan, A., et al. (2000). Genetic counseling for women with an intermediate family history of breast cancer. American Journal of Medical Genetics,90, 361-368.
7.
Cassileth, B. R., Lusk, E. J., Miller, D. S., & Hurwitz, S. (1982). Attitudes toward clinical trials among patients and the public. Journal of the American Medical Association,248, 968-970.
8.
Durfy, S. J., Bowen, D. J., McTiernan, A., Sporleder, J., & Burke, W. (1999). Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in Western Washington. Cancer Epidemiology, Biomarkers & Prevention,8, 369-375.
9.
Edwards, S. J., Lilford, R. J., & Hewison, J. (1998). The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals. British Medical Journal,317, 1209-1212.
10.
Emanuel, E. J., & Patterson, W. B. (1998). Ethics of randomized clinical trials. Journal of Clinical Oncology,16, 365-366.
11.
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C., et al. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute,81, 1879-1886.
12.
Hannon, M., Bowen, D., Mannikko, A., & Dann, R. 2002.Measuring perceptions of breast cancer risk. Manuscript submitted for publication.
13.
Helmes, A. W., Bowen, D. J., Bowden, R., & Bengel, J. (2000). Predictors of participation in genetic research in a primary care physician network. Cancer Epidemiology, Biomarkers & Prevention,9, 1377-1379.
14.
Henzlova, M. J., Blackburn, G. H., Bradley, E. J., & Rogers, W. J. (1994). Patient perception of a long-term clinical trial: Experience using a close-out questionnaire in the Studies of Left Ventricular Dysfunction (SOLVD) Trial. SOLVD Close-out Working Group. Controlled Clinical Trials,15, 284-293.
15.
Lerman, C., Trock, B., Rimer, B., Jepson, C., Brody, D., & Boyce, A. (1991). Psychological side effects of breast cancer screening. Health Psychology,10, 259-267.
16.
Newburg, S. M., Holland, A. E., & Pearce, L. A. (1992). Motivation of subjects to participate in a research trial. Applied Nursing Research,5, 89-93.
17.
Rimer, B. K. (1996). Participating in a women's breast cancer risk counseling trial: Who participates? Who declines?Cancer,77, 2348-2355.
18.
Ross, M. W., Jeffords, K., & Gold, J. (1994). Reasons for entry into and understanding of HIV/AIDS clinical trials: A preliminary study. AIDS Care,6, 77-82.
19.
Slevin, M., Mossman, J., Bowling, A., Leonard, R., Steward, W., Harper, P., et al. (1995). Volunteers or victims: Patients' views of randomised cancer clinical trials. British Journal of Cancer,71, 1270-1274.
20.
Souder, J. E. (1992). The consumer approach to recruitment of elder subjects. Nursing Research,41, 314-316.
21.
Sutherland, H. J., Carlin, K., Harper, W., Martin, L. J., Greenberg, C. V., Till, J. E., et al. (1993). A study of diet and breast cancer prevention in Canada: Why healthy women participate in controlled trials. Cancer Causes and Control,4, 521-528.
22.
Verheggen, F. W., Nieman, F., & Jonkers, R. (1998). Determinants of patient participation in clinical studies requiring informed consent: Why patients enter a clinical trial. Patient Education and Counseling,35, 111-125.
